HUP0301465A3 - Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition - Google Patents

Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Info

Publication number
HUP0301465A3
HUP0301465A3 HU0301465A HUP0301465A HUP0301465A3 HU P0301465 A3 HUP0301465 A3 HU P0301465A3 HU 0301465 A HU0301465 A HU 0301465A HU P0301465 A HUP0301465 A HU P0301465A HU P0301465 A3 HUP0301465 A3 HU P0301465A3
Authority
HU
Hungary
Prior art keywords
composition
dosage forms
therapeutic agents
controlled release
forms including
Prior art date
Application number
HU0301465A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HUP0301465A2 publication Critical patent/HUP0301465A2/hu
Publication of HUP0301465A3 publication Critical patent/HUP0301465A3/hu

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Manufacturing & Machinery (AREA)
  • Psychology (AREA)
HU0301465A 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition HUP0301465A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US21711000P 2000-07-10 2000-07-10
US22321200P 2000-08-04 2000-08-04
PCT/US2001/020134 WO2002000213A1 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Publications (2)

Publication Number Publication Date
HUP0301465A2 HUP0301465A2 (hu) 2004-05-28
HUP0301465A3 true HUP0301465A3 (en) 2006-07-28

Family

ID=27395915

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301465A HUP0301465A3 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Country Status (11)

Country Link
EP (1) EP1305021A4 (cs)
JP (1) JP2004501190A (cs)
KR (1) KR20030013460A (cs)
AU (2) AU6872201A (cs)
CA (1) CA2412490A1 (cs)
CZ (1) CZ2003199A3 (cs)
EA (1) EA200300046A1 (cs)
HU (1) HUP0301465A3 (cs)
IL (1) IL153497A0 (cs)
MX (1) MXPA02012793A (cs)
WO (1) WO2002000213A1 (cs)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
MXPA04001388A (es) * 2001-08-16 2004-05-27 Oregon State Dispositivo de retencion gastrica expandible.
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
WO2004091601A1 (fr) * 2003-04-17 2004-10-28 Jallal Messadek Formulations orales flottantes pour la liberation controlee de la betaine
US20050113452A1 (en) * 2003-10-20 2005-05-26 Moshe Flashner-Barak Composition and dosage form for sustained effect of levodopa
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
EP2242489A1 (en) 2005-02-15 2010-10-27 Jallal Messadek Combination therapeutic compositions and method of use
BRPI0610249A2 (pt) 2005-04-27 2010-06-08 Jallal Messadek associação ou combinação farmacêutica, composição farmacêutica, processo de co-cristalização e o uso de insulina ou análogo de insulina
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
KR20090057349A (ko) * 2006-05-31 2009-06-05 솔베이 파머슈티컬스 게엠베하 레보도파／칼비도파의 ２４시간의 장기간 장내투여
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
WO2008030830A2 (en) * 2006-09-08 2008-03-13 Drugtech Corporation Sustained-release composition and method of use thereof
WO2008039186A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
WO2008087882A1 (ja) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. 胃内滞留型レボドパ徐放性製剤
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
DE102007026037A1 (de) 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
WO2009017716A2 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
CA2724740C (en) 2008-06-30 2017-02-21 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
WO2010019915A1 (en) 2008-08-15 2010-02-18 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
CN102238946B (zh) * 2008-11-07 2014-11-26 株式会社三养生物制药 用于哌醋甲酯的控制释放的药物组合物
EP2661262B1 (en) * 2011-01-06 2017-11-15 Mahmut Bilgic Improved bisphosphonate formulations
CN103385871B (zh) * 2012-05-07 2017-06-23 新疆医科大学 复方左旋多巴微囊漂浮片
US10507127B2 (en) 2012-06-07 2019-12-17 Epitomee Medical Ltd. Expandable device
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
JP6204141B2 (ja) * 2013-04-22 2017-09-27 テイカ製薬株式会社 口腔内速崩壊性固形製剤用組成物
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP6506271B2 (ja) 2013-10-07 2019-04-24 インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用
CN105899198A (zh) 2013-12-05 2016-08-24 图利普医疗有限公司 用于药物活性试剂的原位释放的滞留装置和系统
PT3261625T (pt) * 2015-02-27 2024-11-18 Cingulate Therapeutics LLC Formulações estimulantes de libertação de tripulso
JP6823539B2 (ja) * 2017-05-26 2021-02-03 株式会社ファンケル 胃内滞留性錠剤
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
WO2018232413A1 (en) 2017-06-16 2018-12-20 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
ES2861153T3 (es) 2018-06-18 2021-10-05 Composiciones de liberación prolongada que comprenden piridostigmina
DK3628004T3 (da) 2018-06-27 2021-12-20 Amneal Complex Products Res Llc Selvregulerende osmotiske mave-tarm tilbageholdende leveringssystemer til lægemiddel
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2020264092A1 (en) * 2019-06-26 2020-12-30 Celista Pharmaceuticals Llc Atomoxetine hydrochloride extended release compositions and methods of use
WO2021176360A1 (en) 2020-03-02 2021-09-10 Craft Health Pte Ltd Oral dosage forms for extended drug release
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
WO2022140448A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11571402B2 (en) * 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
KR20010021911A (ko) * 1997-07-23 2001-03-15 추후제출 구강내에서의 약제의 제어방출용 탄닌산-중합체 조성물

Also Published As

Publication number Publication date
JP2004501190A (ja) 2004-01-15
KR20030013460A (ko) 2003-02-14
MXPA02012793A (es) 2004-07-30
EA200300046A1 (ru) 2003-10-30
AU6872201A (en) 2002-01-08
AU2001268722B2 (en) 2005-08-11
EP1305021A4 (en) 2009-09-23
CZ2003199A3 (cs) 2003-12-17
WO2002000213A1 (en) 2002-01-03
CA2412490A1 (en) 2002-01-03
HUP0301465A2 (hu) 2004-05-28
AU2001268722B8 (en) 2005-09-29
EP1305021A1 (en) 2003-05-02
IL153497A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
AU6872201A (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
AU8405201A (en) Contraception process and administration form for the same
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
MXPA03003895A (es) Formulaciones de hidrocodona de liberacion controlada.
HUP0301242A3 (en) Controlled release drug dosage form
AU2001253479A1 (en) Targeted therapeutic agent release devices and methods of making and using the same
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
GB0002386D0 (en) Therapeutic composition
FI20000780L (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
MXPA03004303A (es) DERIVADOS SUSTITUIDOS DE ACIDO AMINO-FURAN-2-IL-ACETICO Y ACIDO AMINO-TIEN-2-IL-ACETICO Y SU USO PARA EL TRATAMIENTO DE MIGRAnA Y DOLOR.
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
HUP0204417A3 (en) Oral ciprofloxacin-composition of controlled release
IL137275A0 (en) Pharmaceutical composition for the treatment of anal fissures
EP1357898A4 (en) ORAL DOSAGE FORM WITH ENHANCED REGULATED RELEASE
GB0030067D0 (en) Therapeutic agent
IL155819A0 (en) Methods of treatment comprising administration of substance p
PH12001001922B1 (en) Crystalline therapeutic agent.
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis
AU6884801A (en) Therapeutic compounds and methods
EP1338275A4 (en) Pharmaceutical composition, its use and method of making the same

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees